Smoking diminishes the beneficial effect of statins: Observations from the landmark trials

Angiology

Volumn 52, Issue 9, 2001, Pages 575-587

  Milionis, Haralampos J ^a   Rizos, Evangelos ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORBIDITY; MORTALITY; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; SMOKING HABIT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; GEMFIBROZIL; HUMANS; LOVASTATIN; MYOCARDIAL ISCHEMIA; PRAVASTATIN; RISK FACTORS; SIMVASTATIN; SMOKING;

EID: 0034829791     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970105200901     Document Type: Article

References (53)

1. Randomised trial of cholesterol lowering in 4, 444 patients with coronary heart disease: The Scandinavian simvastatin survival study
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS. Air Force/Texas coronary atherosclerosis study
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
7. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
8. Measuring plasma fibrinogen to predict stroke and myocardial infarction
9. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice
10. Bezafibrate: Treating hyperlipidaemias as well as other cardiovascular risk factors
11. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolaemia
12. Giving up smoking and the risk of heart attacks. A report from The British Regional Heart Study
13. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT)
14. Lipids and stroke: Neglect of a useful preventive measure?
15. Long-term effect on mortality of stopping smoking after unstable angina and myocardial infarction
16. Cigarette smoking and cardiovascular disease
17. Cigarette smoking: An epidemiological overview
18. Smoking, diabetes and hyperlipidaemia
19. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: A meta-analysis of population-based prospective studies
20. Alteration of plasma low-density lipoprotein from smokers
21. Intima-media thickness of peripheral arteries in asymptomatic cigarette smokers
22. Smoking characteristics, antioxidant vitamins, and carotid artery wall thickness in life-long smokers
23. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorrheology in habitual smokers
24. Persistent blood pressure increase induced by heavy smoking
25. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: Results from a prospective cohort study of Scottish men with 21 years of follow-up
26. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction
27. Statins as cellular antithrombotics
28. Smoking elicits the insulin resistance syndrome: New aspects of the harmful effects of smoking
29. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis
30. Cigarette smoke-mediated oxidant stress, phagocytes, vitamin C, vitamin E, and tissue injury
31. Acute changes in atherogenic and thrombogenic factors with cessation of smoking
32. Alcoholism and smoking
33. Interactions between people's diet and their smoking habits: The dietary and nutritional survey of British adults
34. Do cigarette smokers have diets that increase the risks of coronary heart disease and cancer?
35. Direct effect of statins on cells primarily involved in atherosclerosis
36. Low-density lipoprotein independent effects of statins
37. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia
38. Current perspectives on statins
39. Platelets and lipid powering interventions
40. Treatment of dyslipidaemias in patients with established vascular disease: A review of the fibrates
41. The effect of atorvastatin on serum lipids, lipoprotein (a), and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
42. Regulation of lipid and lipoprotein metabolism by PPAR activators
43. Fibrates, dyslipoproteinaemia and cardiovascular disease
44. Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation, and atherosclerosis
45. Diabetic dyslipidaemia
46. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
47. Site of nicotine absorption from a vapour inhaler- comparison with cigarette smoking
48. The nicotine inhaler in smoking cessation
49. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems
50. A review of the use of saliva cotinine as a marker of tobacco smoke exposure
51. Relation of cotinine concentrations to cigarette smoking and to exposure to other people's smoke
52. Passive smoking and the risk of coronary heart disease - A metaanalysis of epidemiologic studies